These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 387504)

  • 1. Effect of the alpha-glucosidase-inhibitor BAY-g-5421 on blood glucose control of sulphonylurea-treated diabetics and insulin-treated diabetics.
    Sachse G; Willms B
    Diabetologia; 1979 Nov; 17(5):287-90. PubMed ID: 387504
    [No Abstract]   [Full Text] [Related]  

  • 2. Improved metabolic profiles in insulin-treated diabetic patients given an alpha-glucosidehydrolase inhibitor.
    Walton RJ; Sherif IT; Noy GA; Alberti KG
    Br Med J; 1979 Jan; 1(6158):220-1. PubMed ID: 369651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment of sulphonylurea-treated diabetics with the alpha-glucosidase inhibitor Bay g 5421 (acarbose).
    Vierhapper H; Bratusch-Marrain P; Waldhäusl W
    Diabetologia; 1981 May; 20(5):586. PubMed ID: 7286495
    [No Abstract]   [Full Text] [Related]  

  • 4. Improvement of metabolic control in insulin dependent diabetics treated with the alpha-glucosidase inhibitor acarbose for two months.
    Gérard J; Luyckx AS; Lefebvre PJ
    Diabetologia; 1981 Nov; 21(5):446-51. PubMed ID: 7028558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A glycoside-hydrolase inhibitor in treatment of dumping syndrome.
    McLoughlin JC; Buchanan KD; Alam MJ
    Lancet; 1979 Sep; 2(8143):603-5. PubMed ID: 90270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of the alpha-glucosidase inhibitor BAY g 5421 (Acarbose) on postprandial blood glucose, serum insulin, and triglyceride levels: dose-time-response relationships in man.
    Hillebrand I; Boehme K; Frank G; Fink H; Berchtold P
    Res Exp Med (Berl); 1979 Apr; 175(1):87-94. PubMed ID: 375343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of the alpha-glucosidase inhibitor BAY g 5421 (Acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in man.
    Hillebrand I; Boehme K; Frank G; Fink H; Berchtold P
    Res Exp Med (Berl); 1979 Apr; 175(1):81-6. PubMed ID: 375342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of acarbose, an alpha-glucosidase inhibitor (Bay G 5421), on orally loaded glucose, maltose and sucrose and on blood glucose control in non-insulin-dependent diabetics.
    Hayakawa T; Noda A; Kondo T; Okumura N
    Nagoya J Med Sci; 1985 Jan; 47(1-2):35-41. PubMed ID: 3887176
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effect of glucosidase inhibitor, Bay g 5421 (acarbose), on the blood glucose in obese diabetic patients ty pe 2 (NIDDM) (author's transl)].
    Laube H; Fouladfar M; Aubell R; Schmitz H
    Arzneimittelforschung; 1980; 30(7):1154-7. PubMed ID: 7191299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Modification of carbohydrate metabolism and oral glucose tolerance test in type II diabetics using the glucosidase inhibitor acarbose].
    Schwartzkopff W; Calder D
    Med Welt; 1984 Feb; 35(6):169-74. PubMed ID: 6369065
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of new alpha-glucosidase inhibitors (BAY m 1099 and BAY o 1248) on meal-stimulated increases in glucose and insulin levels in man.
    Hillebrand I; Boehme K; Graefe KH; Wehling K
    Klin Wochenschr; 1986 Apr; 64(8):393-6. PubMed ID: 3517475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of alpha-glucosidase inhibition on intestinal disaccharidase activity in normal and diabetic mice.
    Lee SM; Bustamante SA; Koldovský O
    Metabolism; 1983 Aug; 32(8):793-9. PubMed ID: 6346004
    [No Abstract]   [Full Text] [Related]  

  • 13. Diabetes mellitus. Medication update.
    Slagle M
    South Med J; 2002 Jan; 95(1):50-5. PubMed ID: 11827245
    [No Abstract]   [Full Text] [Related]  

  • 14. alpha-Glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitus.
    Dimitriadis GD; Tessari P; Go VL; Gerich JE
    Metabolism; 1985 Mar; 34(3):261-5. PubMed ID: 3883097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison on sulphonylurea and insulin treatment on lipid levels in maturity-onset diabetic men and women.
    Berry EM; Bar-on H
    Isr J Med Sci; 1981 May; 17(5):384-7. PubMed ID: 7021470
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of alpha-inhibitors on blood glucose and insulin levels.
    Laube H; Federlin K; Hillebrand I
    Adv Exp Med Biol; 1988; 246():287-93. PubMed ID: 3074658
    [No Abstract]   [Full Text] [Related]  

  • 17. Metabolic effects of combined sulphonylurea and metformin therapy in maturity-onset diabetice.
    Nattrass M; Hinks L; Smythe P; Todd PG; Alberti KG
    Horm Metab Res; 1979 May; 11(5):332-7. PubMed ID: 573232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of alpha-glucosidase-inhibitors.
    Fölsch UR
    Hepatogastroenterology; 1982 Apr; 29(2):47-8. PubMed ID: 7044933
    [No Abstract]   [Full Text] [Related]  

  • 19. [Alpha-amylase and glucosidase inhibitors].
    Maranesi M
    Clin Ter; 1986 Apr; 117(1):23-30. PubMed ID: 3522064
    [No Abstract]   [Full Text] [Related]  

  • 20. Scope and specificity of acarbose in slowing carbohydrate absorption in man.
    Jenkins DJ; Taylor RH; Goff DV; Fielden H; Misiewicz JJ; Sarson DL; Bloom SR; Alberti KG
    Diabetes; 1981 Nov; 30(11):951-4. PubMed ID: 7028548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.